Molbio Diagnostics Eyes ₹940 Crore Through IPO Amid Strong Growth

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is gearing up for a significant financial maneuver with its upcoming initial public offering (IPO). The company aims to generate ₹200 crore through a fresh issue of shares, targeting capital expenditure enhancements. Additionally, an offer for sale is set to raise ₹740 crore, which will reduce the promoter group's stake from 46.6% to 43%.

Strategic Expansion and Revenue Streams

Founded in 2000, Molbio Diagnostics has established a strong foothold in the healthcare diagnostics industry. Operating six manufacturing sites across India, the company serves clients in over 90 countries. Its clientele includes government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. A substantial portion of its revenue stems from its tuberculosis diagnostic test kits, which account for nearly 74% of sales. The company's Truenat platform, a portable diagnostics system, is particularly notable for its efficacy in resource-limited settings, delivering accurate results within an hour.

Financial Performance and Market Position

Molbio's financials have shown robust growth. Between FY24 and FY26, revenue from operations surged by 31.5% annually to ₹1,445.7 crore, while net profit increased by 40.2% to ₹164.1 crore. The company's EBITDA rose by 33.2% to ₹328.2 crore, with margins improving from 22% in FY24 to 22.6% in FY26. For FY26, year-on-year revenue jumped by 41.7%, with EBITDA and net profit growing by 27.9% and 18.4%, respectively.

Investment Considerations and Valuation

Molbio Diagnostics is seeking a price-earnings (P/E) multiple of up to 57, positioning itself competitively within the healthcare diagnostics and medical device sector. While it lacks direct peers in India, companies like Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre trade with P/E ratios ranging from 54 to 81. This IPO presents an opportunity for high-risk investors to tap into a company with strong growth metrics and a strategic focus on expanding its diagnostic solutions portfolio.